AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer.

CONCLUSIONS: Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust anti-tumor response. PMID: 32439698 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32439698?dopt=Abstract

Source: Clinical Cancer Research - May 20, 2020 Category: Cancer & Oncology Authors: McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, Salgia R, Hong S, Bruce JY, Kimple RJ, Wheeler DL Tags: Clin Cancer Res Source Type: research